Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment

Annals of the Rheumatic Diseases

Volumn 65, Issue 7, 2006, Pages 924-928

  Laas, Karin ^a,b   Peltomaa, R ^a   Kautiainen, H ^c   Puolakka, K ^d   Leirisalo Repo, M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Department of Rheumatology   (Estonia)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^d Lappeenranta Central Hospital   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PODOPHYLLOTOXIN;

ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; BRAIN HEMORRHAGE; CHRONIC ARTHRITIS; CLINICAL PRACTICE; CONTROLLED STUDY; DERMATITIS; DRUG COST; DRUG HYPERSENSITIVITY; FEMALE; HEALTH CARE COST; HUMAN; KIDNEY AMYLOIDOSIS; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ORTHOPEDIC SURGERY; OUTPATIENT; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; UNIVERSITY HOSPITAL; WORK DISABILITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; FINLAND; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OFFICE VISITS; SICKNESS IMPACT PROFILE; WORK SCHEDULE TOLERANCE;

EID: 33745700471     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.041574     Document Type: Article

References (15)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
3. Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
4. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedvelt FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
6. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
7. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
8. Husni ME, Maier AL, Mease PJ, Overmann SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171-6.
9. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35.
10. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
11. Welsing PM, Severens JL, Hartman M, van Riel PL, Loan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51:964-73.
12. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
13. Hakala M, Nieminen P, Manelius J. Joint impairment is strongly correlated with disability measured by self-report questionnaires. Functional status assessment of individuals with rheumatoid arthritis in a population based series. J Rheumatol 1994;21:64-9.
14. Efron B, Tibshirani R. An introduction to the Bootstrap. New York: Chapmann and Hall, 1993.
15. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.